Pipelinepharma - pipeline intelligence and pharmaceutical dossier sourcing platform, providing visibility into existing and future competition across a broad range of pharmaceutical dossiers — including EU and US CTDs — covering generics (Gx), biosimilars, innovative medicines, and finished dosage formulations. We help pharmaceutical companies de-risk portfolio, licensing, and investment decisions by revealing the true competitive landscape — including competitive density, future market pressure, post-LOE supply predictability, upcoming competition, and expected price erosion — based on aggregated, permission-based data, with strict respect for IP ownership and confidentiality. Pipeline intelligence supports strategy alignment from portfolio planning through commercial execution, enabling informed, risk-aware decision-making across strategy, portfolio, R&D, and business development teams. For companies with a defined product or market focus, Pipelinepharma provides a separate sourcing and execution capability, enabling direct engagement with 2,000+ verified dossier owners, manufacturers, and CDMOs, with visibility across 90,000+ pharmaceutical product dossiers. All interactions take place without intermediaries or brokerage fees, enabling transparent and efficient B2B collaboration. 📧 Let’s talk: support@pipelinepharma.com
Looking for a particular Pipelinepharma employee's phone or email?
The Pipelinepharma annual revenue was $1 million in 2026.
Mindaugas Zagorskis is the Co-Founder and CEO of Pipelinepharma.
10 people are employed at Pipelinepharma.
Pipelinepharma is based in New York, New York.
The NAICS codes for Pipelinepharma are [325, 32541, 3254, 32].
The SIC codes for Pipelinepharma are [283, 28].